Table 2.
Active and completed clinical trials of drugs potentially targeting histone mark writers and erasers in pediatric BCP-ALL (as accessed on 25 October 2016, at www.clinicaltrails.gov).
| Study Identifier | Start Year | Drug Targeting (or Potentially Targeting) Histone Modifications | ALL Population | Phase | Status |
|---|---|---|---|---|---|
| NCT00053963 | 2002 | FR901228 (HDACi) | Refractory disease (0–21 years) | 1 | completed |
| NCT00217412 | 2005 | Vorinostat (HDACi) | Relapsed or refractory disease (1–21 years) | 1 | completed |
| NCT00882206 | 2009 | Vorinostat (HDACi) | Relapsed or refractory disease (2–60 years) | 2 | completed |
| NCT01251965 | 2010 | Ruxolitinib (JAK1/JAK2 inhibitor) | Relapsed or refractory disease (14 years or older) | 1/2 | completed |
| NCT01321346 | 2011 | Panobinostat (HDACi) | Refractory disease (8–21 years) | 1 | completed |
| NCT02141828 | 2014 | EPZ-5676 (DOT1L blocker) | Relapsed or refractory disease (0–18 years) MLL-rearranged | 1 | completed |
| NCT02419755 | 2015 | Vorinostat (HDACi) | Relapsed or refractory disease (0–21 years) MLL-rearranged | 2 | recruiting |
| NCT02420717 | 2015 | Ruxolitinib (JAK1/JAK2 inhibitor) | Ph-like (10 years or older) | 2 | recruiting |
| NCT02723994 | 2016 | Ruxolitinib (JAK1/JAK2 inhibitor) | CRLF2-rearranged and/or JAK Pathway-mutant (1–21 years) | 2 | recruiting |